Please find attached intimation w.r.t. disinvestment.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts more than Nifty Microcap 250 and 2.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Pharmaids Pharmaceuticals has sold its entire 66.50% partnership stake in Anugraha Chemicals (its material subsidiary) to Mrs. Sneha Hadimani, nominee of Mr. Sourabh Hadimani, for a cash consideration of Rs. 6.65 lakh for the partnership stake itself. A wider aggregate settlement of around Rs. 10.50 crore (factoring in earlier capital, loans of ~Rs. 3.07 crore, accumulated losses, and employee dues of ~Rs. 26 lakh) was referenced in earlier communications, with the balance amounts to be received in due course. The deal, already executed on September 18, 2025, was approved by shareholders via postal ballot on August 14, 2025 and the Investment Agreement has been terminated. Anugraha contributed ~68.91% of consolidated revenue (Rs. 13.40 crore) and 6.80% of consolidated net worth (Rs. 3.74 crore) as on March 31, 2025, and has now ceased to be a material subsidiary.
The subsidiary being divested contributed nearly 69% of consolidated revenue, so this is a very significant reshaping of the company's business profile — the consolidated topline may shrink sharply going forward. However, the upfront stake consideration is small (Rs. 6.65 lakh), with larger recoveries (loans and dues) still pending, so near-term cash inflows and actual earnings impact depend on timely receipt of those balances.